News

As a part of the agreement, the physiological characteristics of the adult autologous vascular cells which form the basis of the IntelliCell product will be discovered. IntelliCell CEO

The collaboration will focus on the radiation oncology research to advance treatment technology. With the signing of collaboration agreement with the University of Heidelberg in March 2012, the

The enzalutamide has been studied in patients with castration-resistant prostate cancer who have received docetaxel therapy. The oral once-daily investigational agent is an androgen receptor signalling inhibitor. Enzalutamide

The Monotherapy admInistration of Sorafenib in patientS wIth nOn-small cell luNg cancer (MISSION) trial observed an improvement in the secondary endpoint of progression-free survival (PFS). The Nexavar plus

Selexis CEO Igor Fisch said, "Combining our expertise in difficult-to-express proteins with our SUREtechnology Platform(TM) is an important step in advancing ADIENNE’s project to the clinic." ADIENNE Pharma

BD Live! enables comparative asset analysis via an industry-first Relative Valuation Index (RVI) which accounts for the stage of asset development and factors in competitive environment, scientific evidence,

Dulaglutide, a long-acting glucagon-like peptide 1 (GLP-1) analog, met its primary endpoint of non-inferiority for mean 24-hour systolic blood pressure (SBP, or pressure while the heart contracts) after

MOR208 (formerly XmAb5574) is a potent anti-CD19 antibody with a proprietary modification to the Fc portion, that is being developed to treat B-cell malignancies. The open-label, multi-dose, single-arm,

Testim is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of testosterone. As per the agreement, GSK has been granted